Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Thursday, April 18, 2013
Tenofovir/emtricitabine topped other regimens for patients coinfected with HIV, HBV
In a multinational longitudinal study, researchers collected data from 165 HIV/HBV-coinfected patients from the United States, Australia and Thailand. The majority of the cohort (90.3%) either used or planned to use highly active antiretroviral therapy (HAART) within 1 year of study initiation. Patient follow-up occurred every 6 months for a median of 2.8 years, resulting in 1,015 study visits. Using logistic regression, researchers determined factors associated with detectable HBV DNA (characterized as greater than 357 IU/mL).